Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_assertion type Assertion NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_head.
- NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_assertion description "[After treatment with topical tacrolimus twice daily for 8 weeks, significant decreases were found in serum IL-5 levels, immunoreactive cell counts of eotaxin, IL-5, CCR3 and RANTES in AD skin, and tissue eosinophil counts.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_provenance.
- NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_assertion evidence source_evidence_literature NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_provenance.
- NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_assertion SIO_000772 15948978 NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_provenance.
- NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_assertion wasDerivedFrom befree-20140225 NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_provenance.
- NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_assertion wasGeneratedBy ECO_0000203 NP295610.RAL2eICaH6i9kEvFEqw98OI6mYlW7nYZVzEtGNC-oJ6lQ130_provenance.